Cancer Evolution
Tumour progression is driven by a process of clonal evolution. The importance of this process has been increasingly recognized over the past decade: tumour heterogeneity, the major cause of therapeutic resistance to antitumour agents, results from the genetic, epigenetic and microenvironmental selective pressure that tumour cells undergo during cancer progression.
In this collection, the cancer editorial community of the Nature journals presents the most recently published articles on cancer evolution. The topic is discussed from different complementary angles (preclinical, translational and clinical), and across a broad range of tumour types. This collection has been produced with exclusive support from EMD Serono. The collection content is editorially independent and the sole responsibility of Springer Nature.
Please join the webcast that accompanies the cancer Evolution collection on Friday 28th April at 12PM EDT.
In this webcast, Peter Campbell discusses the study of cancer evolution through genome-wide analyses of tumours. Next, Kornelia Polyak describes the biological mechanisms that govern tumour evolution. Finally, Alberto Bardelli explains how the process can be harnessed to improve therapy. These presentations will be followed by a live discussion on how these three areas of research intersect, and where the field is heading.
